| Literature DB >> 24160187 |
Merlyn J Kaalla, K Alaine Broadaway, Mina Rohani-Pichavant, Karen N Conneely, April Whiting, Lori Ponder, David T Okou, Sheila Angeles-Han, Kelly Rouster-Stevens, Milton R Brown, Larry B Vogler, Lynn B Jorde, John F Bohnsack, Michael P Epstein, Sampath Prahalad1.
Abstract
BACKGROUND: Although more than 100 non-HLA variants have been tested for associations with juvenile idiopathic arthritis (JIA) in candidate gene studies, only a few have been replicated. We sought to replicate reported associations of single nucleotide polymorphisms (SNPs) in the PTPN22, TNFA and MIF genes in a well-characterized cohort of children with JIA.Entities:
Year: 2013 PMID: 24160187 PMCID: PMC3874734 DOI: 10.1186/1546-0096-11-40
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Case-control analysis of PTPN22, TNFA and MIF variants and JIA
| | | | ||||
|---|---|---|---|---|---|---|
| 636 | 0.13 | 733 | 0.11 | 1.29 (1.02-1.62) | ||
| 638 | 0.18 | 742 | 0.17 | 1.06 (0.88-1.29) | 0.5353 | |
| 638 | 0.04 | 749 | 0.06 | 0.66 (0.46, 0.95) | ||
| 628 | 0.14 | 729 | 0.17 | 0.82 (0.66, 1.01) | 0.0574 | |
Results of case-control association of PTPN22, MIF and TNFA variants among JIA sub-phenotypes
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| Systemic | 50 | 1.06 (0.53, 1.91) | 49 | 1.53 (0.93, 2.45) | 50 | 1.69 (0.76, 3.36) | 50 | |
| RF-Positive | 48 | 47 | 1.06 (0.60, 1.75) | 48 | * | 47 | 0.98 (0.54, 1.66) | |
| RF-Negative | 154 | 1.09 (0.74, 1.57) | 158 | 0.86 (0.61, 1.19) | 157 | 1.14 (0.67, 1.86) | 156 | 0.85 (0.60, 1.18) |
| ERA | 55 | 1.09 (0.55, 1.97) | 56 | 1.23 (0.74, 1.98) | 56 | 0.94 (0.35, 2.06) | 56 | |
| Oligoarticular | 284 | 283 | 1.06 (0.83, 1.36) | 284 | 276 | 0.96 (0.73, 1.25) | ||
1 p = 0.0041; 2 p = 0.0400; 3 p = 0.0006; 4 p = 0.0089; 5 p = 0.0144; Statistically significant results are bolded. * Represents an analysis that was not conducted due to small cell size.
Studies included in meta-analyses
| | | | | | ||||
|---|---|---|---|---|---|---|---|---|
| Seldin et al. | [ | Finland | 2005 | 230 | 0.18 | 1400 | 0.15 | |
| Hinks et al. | [ | UK | 2005 | 661 | 0.15 | 595 | 0.10 | |
| Cinek et al. | [ | Czech/Azeri | 2007 | 130 | 0.21 | 400 | 0.10 | |
| Pazar et al. | [ | Hungary | 2008 | 150 | 0.09 | 200 | 0.08 | |
| Thompson et al. | [ | USA | 2010 | 809 | 0.14 | 531 | 0.09 | |
| Ellis | [ | Australian | 2013 | 324 | 0.10 | 568 | 0.07 | |
| Viken et al. | [ | Norway | 2005 | 320 | 0.16 | 555 | 0.12 | |
| Kaalla et al. | Present | USA | | 637 | 0.13 | 733 | 0.11 | |
| Miterski et al. | [ | Germany | 2004 | 150 | 0.24 | 390 | 0.21 | |
| Berdeli et al. | [ | Turkey | 2006 | 67 | 0.13 | 153 | 0.10 | |
| Kaalla et al. | Present | USA | | 639 | 0.18 | 742 | 0.17 | |
| Zeggini et al. | [ | UK | 2002 | 137 | 0.03 | 76 | 0.09 | |
| Miterski et al. | [ | Germany | 2004 | 130 | 0.02 | 375 | 0.03 | |
| Modesto et al. | [ | Spain | 2005 | 55 | 0.07 | 59 | 0.09 | |
| Schmeling et al. | [ | Germany | 2006 | 228 | 0.03 | 196 | 0.03 | |
| Kaalla et al. | Present | USA | | 639 | 0.04 | 749 | 0.06 | |
| [ | ||||||||
| [ | ||||||||
| Zeggini et al. | [ | UK | 2002 | 138 | 0.24 | 75 | 0.13 | |
| Miterski et al. | [ | Germany | 2004 | 122 | 0.17 | 312 | 0.16 | |
| Modesto et al. | [ | Spain | 2005 | 55 | 0.13 | 59 | 0.12 | |
| Schubert et al. | [ | Germany | 2006 | 86 | 0.15 | 270 | 0.15 | |
| Schmeling et al. | [ | Germany | 2006 | 228 | 0.14 | 196 | 0.17 | |
| Mourao et al. | [ | Portugal | 2009 | 115 | 0.12 | 118 | 0.11 | |
| Kaalla et al. | Present | USA | 629 | 0.14 | 729 | 0.17 | ||
*Bolded studies were removed from analysis due to evidence for heterogeneity, using Cochran’s Q test (p < 0.10 threshold).
Figure 1Forest Plots of meta-analyses, including all studies.
Meta-analysis results for PTPN22, MIF and TNFA variants and JIA
| | | | | | ||||
|---|---|---|---|---|---|---|---|---|
| All Studies | 3261 | 0.14 | 4982 | 0.11 | 4-7, 18,19, 29 | |||
| Including Donn et al. [ | 1382 | 0.19 | 1544 | 0.17 | 9, 13, 16 | |||
| Removing Donn et al. | 856 | 0.19 | 1285 | 0.18 | 1.12 (0.96, 1.32) | 0.1548 | | |
| Including Ozen et al. [ | 1399 | 0.07 | 1648 | 0.07 | 0.84 (0.68, 1.04) | 0.1033 | 9, 11, 20, 22, 23 | |
| Removing Ozen et al. | 1189 | 0.03 | 1455 | 0.04 | | |||
| Including Ozen et al. [ | 1583 | 0.17 | 1952 | 0.16 | 1.01 (0.88, 1.15) | 0.925 | 9, 11, 12, 20-23 | |
| Removing Ozen et al. | 1373 | 0.15 | 1759 | 0.16 | 0.95 (0.83, 1.10) | 0.5137 | ||
Meta-Analysis results for subtypes: combining Hinks et al. [[5]] data with data from our cohort
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| Systemic | 118 | 0.09 | 0.89 (0.55, 1.44) | 50 | 0.11 | 1.05 (0.55, 2.01) | 0.94 (0.64, 1.39) | 0.7675 |
| RF-Positive | 35 | 0.17 | 1.79 (0.94, 3.43) | 48 | 0.21 | 2.24 (1.33, 3.77) | ||
| RF-Negative | 135 | 0.2 | 2.12 (1.49, 3.02) | 154 | 0.12 | 1.13 (0.77, 1.66) | ||
| ERA | 48 | 0.14 | 1.36 (0.74, 2.51) | 55 | 0.11 | 1.04 (0.56, 1.94) | 1.19 (0.77, 1.84) | 0.4431 |
| Oligoarticular | 276 | 0.15 | 1.56 (1.16, 2.10) | 284 | 0.14 | 1.36 (1.01, 1.82) | ||
| Controls | 595 | 0.1 | NA | 733 | 0.11 | NA | NA | NA |
PTPN22 allele frequency and odds ratios from Hinks et al. [5] and Kaalla et al. (Present) divided by five JIA categories. No covariates were included in the analyses. Pooled data significant at the α = 0.05 threshold level is bolded.